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Abstract. Medical countermeasures to treat biothreat agent infections require broad-spectrum 
therapeutics that do not induce agent resistance. A cell-based high-throughput screen (HTS) 
against ricin toxin combined with hit optimization allowed selection of a family of 
compounds that meet these requirements. The hit compound Retro-2 and its derivatives have 
been demonstrated to be safe in vivo in mice even at high doses. Moreover, Retro-2 is an 
inhibitor of retrograde transport that affects syntaxin-5-dependent toxins and pathogens. As a 
consequence, it has a broad-spectrum activity that has been demonstrated both in vitro and in 
vivo against ricin, Shiga toxin-producing O104:H4 entero-hemorrhagic E. coli and 
Leishmania sp. and in vitro against Ebola, Marburg and poxviruses and Chlamydiales. An 
effect is anticipated on other toxins or pathogens that use retrograde trafficking and syntaxin-
5. Since Retro-2 targets cell components of the host and not directly the pathogen, no 
selection of resistant pathogens is expected. These lead compounds need now to be developed 
as drugs for human use. 
 
Keywords: Bioterrorism; Biothreat agents; Emerging infectious diseases; Ricin toxin; Shiga-
like toxins; Retrograde cell transport; High-throughput cell-based assays. 
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1. Bioterrorism, biothreat agents and biodefense 
For several decades, the rate of health crises related to emerging infectious diseases has 
increased (H1N1 influenza virus, E. coli O104:H4, Chikungunya virus, Ebola virus, etc) (1, 
2). In parallel, biological attack by disseminating a pathogen or a biotoxin has been 
demonstrated (e.g. anthrax letters in 2001 or ricin letters to president Obama more recently) 
(3). These events led to an increased awareness of health authorities for intensification of 
research into the development of medical countermeasures for a wide range of biothreat 
agents, either naturally emerging or deliberately introduced as an act of bioterrorism (4).  
According to the U.S. Centers for Disease Control and Prevention (CDC), a bioterrorism 
attack is the deliberate release of viruses, bacteria, toxins or other harmful agents to cause 
illness or death in people, animals, or plants. The CDC bioterrorism agents are listed in (5). 
Biodefense is defined as the means or methods of preventing, detecting, or managing an 
attack involving biological weapons.  
Emerging infectious diseases are defined by the US National Institute of Allergy and 
Infectious Disease (NIAID) as infectious diseases that have newly appeared in a population or 
have existed but are rapidly increasing in incidence or geographic range, or that are caused by 
one of the NIAID Category A, B, or C priority pathogens (6). Category A includes high-
priority agents that pose a risk to national security because they can be easily transmitted and 
disseminated, result in high mortality, have potential major public health impact, may cause 
public panic, or require special action for public health preparedness. Category B includes 
agents that are moderately easy to disseminate and have low mortality rates. Category C 
agents are emerging pathogens that might be engineered for mass dissemination because of 
their availability, ease of production and dissemination, high mortality rate, or ability to cause 
a major health impact. 
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Although the causes of emergent diseases and bioterrorism are different, they share some 
characteristics: biothreat agents are highly diverse (bacteria, viruses, toxins, etc.), the agent 
that will provoke the next crisis is always indefinite, unknown pathogens may emerge, 
medical countermeasures are too long to develop in front of an immediate threat and some 
suspected biothreat agents may never provoke a crisis. Therefore, medical countermeasures 
against biothreat agents require broad-spectrum therapeutics that do not induce agent 
resistance (4). In this review we describe the development of new compounds that target the 
intracellular retrograde transport process. These compounds have been shown to be safe in 
animals and they demonstrated efficacy against toxins, such as ricin or Shiga toxins, in in 
vitro and in vivo models. Moreover, recent studies have shown that these compounds provided 
protection against filoviruses, poxviruses, Chlamydiales and Leishmania. Ricin, Shiga toxin-
producing Escherichia coli, filoviruses, poxviruses and Chlamydiales are found both in the 
CDC bioterrorism biothreat agent list and the NIAID emerging disease list (5, 6). Although 
Leishmania are not, a recent outbreak of 446 cases in Madrid, Spain, between 2009 and 2012 
had the characteristics of an emerging infectious disease (7). 
2. Identification of ricin antidotes   
Ricin is a highly toxic lectin produced in the seeds of the plant Ricinus communis. This toxin 
is used as a bio-crime and bio-suicide poison and is considered a potential bio-terrorist agent. 
The plant is used for ornamentation and industry. The oil (castor oil) contained in the seeds is 
treated for the production of ricinoleic acid, a fatty acid entering in the composition of many 
manufactured products such as cosmetics, soaps, shampoos, inks, paints, varnishes, brake 
fluids, etc. The toxin, which is hydrophilic, remains in the seed pulp after oil extraction and 
can be easily purified. Doses as low as a few micrograms are lethal for injected mice; in 
humans, 1 to 20 mg can be fatal after ingestion. There is no antidote for ricin poisoning and 
treatment relies on supportive care.  
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Ricin is a glycosylated protein which is composed of two subunits: ricin toxin A and B chains 
(8). The A subunit has ribosomal RNA N-glycosidase activity and thus it inhibits protein 
biosynthesis (adenine at position 4324 of the 28S ribosomal RNA is removed). The B subunit 
binds to cell surface receptors (galactose and N-acetylgalactosamine moieties of glycoproteins 
and glycolipids). After cell adhesion, ricin is internalized (via clathrin-dependent and 
independent mechanisms) and transported from early endosomes to the endoplasmic 
reticulum via the Golgi apparatus (8).  
Different therapeutic approaches to treat ricin toxicity have been considered such as 
vaccination (9, 10) or production of neutralizing antibodies (11, 12). Mass immunization 
against ricin is however unrealistic. Neutralizing antibodies have efficacy against ricin 
poisoning in animal models and have their place in a therapeutic arsenal (13). However, they 
need to be administered within the first 10-24 h of intoxication and cannot access ricin already 
internalized by cells. Due to the potentially high severity of ricin intoxication, co-
administration of small therapeutic molecules with anti-ricin antibodies may greatly improve 
disease outcome. Another approach was to target the catalytic activity of the A chain of ricin. 
Small-molecule compounds have been reported to inhibit enzymatic activity in in vitro tests, 
but they generally failed to protect cells or animals from ricin toxicity (14-22). 
Cell-based high-throughput screens (HTS) have been used to identify small-molecule 
inhibitors of ricin (23). An advantage of cell-based assays in which compounds are selected 
for rescuing cells from intoxication is the selection of bioactive compounds that do not affect 
cell viability (24-26). Figure 1 describes high-throughput cell-based phenotypic assays that 
measure the effects of small-molecule compounds on cell toxicity induced by ricin. Cells are 
exposed to ricin and protein biosynthesis that is the target of the toxin is measured in order to 
assess cell protection against ricin toxicity for each compound. 
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In 2007, Saenz et al. described a luciferase-based HTS with a chemical library of 14,400 
small-molecule compounds. Monkey Vero cells were transfected with cDNA encoding a 
destabilized luciferase with short half-life; luciferase activity decreased rapidly in cells 
incubated in the presence of toxin. Two compounds that protected against ricin inhibition of 
protein synthesis were reported (24). In 2010, Stechmann et al. used HTS to identify small-
molecule inhibitors that protected cells from ricin (25). 16,480 molecules from a commercial 
library of drug-like compounds (ChemBridge DIVERSet™) were tested at a concentration of 
25 µM on A549 human epithelial pulmonary cells (60,000 cells per well in 96-well 
scintillation microplates) for their capacity to rescue cells from intoxication by ricin at a 
concentration of 0.1 nM. [14C]-leucine incorporation in cell proteins was used as a marker of 
protein synthesis. Thus, ricin-intoxicated cells failed to incorporate [14C]-leucine while cells 
protected by a given compound did. Two compounds named Retro-1 and Retro-2 were 
identified and studied in detail on HeLa cells.  
These two inhibitors showed an unexpected degree of specificity. Indeed, these compounds 
blocked retrograde toxin trafficking at the early endosome/trans-Golgi network (TGN) 
interface and did not affect compartment morphology, endogenous retrograde cargos or other 
trafficking steps (Figure 2) (25). This transport pathway is also named the retrograde route 
and it is involved in many physiological and pathological situations (27). 
3. Protection of mice challenged with ricin 
The two compounds selected by Stechmann et al. after HTS were nontoxic for animals after 
intraperitoneal administration up to 400 mg/kg (25). The molecules were solubilized in pure 
DMSO at 30 mM and diluted to final concentration in saline. A model of ricin intoxication by 
nasal instillation was used in order to mimic exposure by aerosols, which is a likely modality 
in bioterror attacks. A dose of ricin leading to 90% deaths at day 21 (LD90) was chosen. With 
this dose, the first clinical signs of toxicity were observed within 24 h. A statistically 
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significant prophylactic protection was observed in first experiments with a single 
intraperitoneal dose of 2 mg/kg of Retro-2 one hour prior toxin challenge: 49% of mice 
survived vs. 11.5% in control group (p = 0.001). Complementary experiments were performed 
indicating a dose-response relationship (Figure 3). After administration of 20 mg/kg of Retro-
2, the survival was 60% at 20 days. Finally, 200 mg/kg of Retro-2 fully protected mice against 
ricin challenge. Therefore, these results clearly demonstrated that a small molecule can 
protect animals exposed to a lethal dose of ricin. Retro-2 was described as a lead compound 
for the development of inhibitors of ricin. Moreover, the retrograde route was identified as a 
potential therapeutic target for other toxins that follow this route.  
4. Inhibitor of retrograde trafficking protects mice infected with entero-hemorrhagic E. 
coli  
Shiga toxins are members of a family that includes Shiga toxin produced by Shigella 
dysenteriae and two Shiga-like toxins (SLTs) named Stx1 and Stx2 produced by entero-
hemorrhagic strains of Escherichia coli (28). Shiga toxin-producing E. coli (STEC) cause 
hemorrhagic colitis, hemolytic-uremic syndrome (HUS) and death (29). The most common 
sources for SLTs are entero-hemorrhagic E. coli with serotypes O157:H7 and O104:H4. 
There is no approved treatment of STEC-induced HUS. Despite efficacy in non-STEC-
induced HUS (atypical HUS), the use of the anti-C5 complement component antibody 
eculizumab® in STEC-induced HUS remains inconclusive (30). In addition, antibiotics may 
worsen the disease by further inducing toxin release by the bacteria (31).  
SLTs share structural and functional characteristics with ricin (8, 28). They are composed of 
an A catalytic subunit and a pentameric B subunit. The subunit A of SLTs inhibits protein 
biosynthesis through ribosomal RNA N-glycosidase activity and the subunit B binds to cell 
surface receptors (glycosphingolipid globotriaosyl ceramide; Gb3 or CD77) (28). After 
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internalization, these toxins are transported from early endosomes through the Golgi 
apparatus to the endoplasmic reticulum (28).  
Since SLTs share with ricin the trafficking via the retrograde route, inhibitors that were shown 
to be effective on ricin intoxication via inhibition of this pathway were also tested as potential 
inhibitors of intoxication by SLTs. As for ricin, Retro-2 has been demonstrated to protect 
HeLa cells from the toxic effects of Stx1 and Stx2 (25).  
Secher et al. have studied the effect of Retro-2 in a murine model of E. coli O104:H4 
infection (32). As shown in Figure 4, O104:H4 infection led to a 70% mortality rate in 
untreated control mice. Systemic treatment with two injections of Retro-2 at 100 mg/kg 
(solubilized in pure DMSO at 30 mM and diluted to final concentration in saline) significantly 
reduced mortality rate to 40%. Body weight loss and clinical scores were reduced by more 
than half.  
5. Effects of Retro-2 on viral infections  
Viruses are internalized into host cells through various routes (33). In the case of enveloped 
viruses, direct fusion at the plasma membrane may allow deposition of the nucleocapsid 
directly into the cytoplasm. However, non-enveloped viruses and some enveloped viruses are 
unable to access the host cytoplasm directly from the cell surface. After endocytosis these 
viruses exploit the host vesicular trafficking that leads them to the endosomes, the Golgi 
apparatus or to the endoplasmic reticulum where they are released into the cytoplasm (34). 
The use of retrograde transport suggested that infection by some viruses could be blocked by 
the Retro-2 compound via similar mechanisms that blocked retrograde trafficking of ricin and 
SLTs. 
Adeno-associated viruses. Gene therapy is a promising biomedical strategy, and adeno-
associated virus (AAV) vectors are currently being evaluated for the treatment of various 
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diseases. AAV vectors must reach the nucleus and retrograde transport of capsids via the 
trans-Golgi network is necessary for gene delivery. Nonnenmacher et al. showed that the 
endosome-to-TGN/Golgi apparatus transport step of AAV is dependent on syntaxin-5 
function and that this step can be inhibited by Retro-2 (35). Therefore these results support the 
concept that inhibition of retrograde transport could protect not only against ricin or SLTs, but 
also against viruses. 
Polyomaviruses and papillomaviruses. Polyomaviruses are non-enveloped DNA viruses that 
cause severe disease in immunocompromised individuals. Thus, JC polyomavirus (JCPyV) is 
the causative agent of the fatal demyelinating disease progressive multifocal 
leukoencephalopathy, and BK polyomavirus (BKPyV) is the causative agent of 
polyomavirus-induced nephropathy and hemorrhagic cystitis. There is no vaccine or antiviral 
therapy for these viruses (36). Human papillomaviruses (HPVs) are also non-enveloped DNA 
viruses. They are associated with the development of cancer of uterine cervix and oropharynx. 
Vaccination against some types of HPV has been successful, but there are no approved drugs 
to treat or prevent papillomavirus infections and these viruses remain a major public health 
concern (37). 
Nelson et al. (38) demonstrated in tissue culture cells that Retro-2 inhibited infection by 
JCPyV, BKPyV and simian virus 40, which is another polyomavirus. Infectivity was reduced 
to 30% for simian virus 40 and 20% for BKPyV and JCPyV with 100 µM of Retro-2 as 
compared to control. Retro-2 inhibited retrograde transport of polyomaviruses to the 
endoplasmic reticulum, which is a step essential for infection (38). Carney et al. confirmed 
these results on polyomaviruses and demonstrated that Retro-2 protected also cell lines from 
infection by papillomaviruses (37). 
Ebola and Marburg filoviruses. Ebola and Marburg viruses are filamentous enveloped 
viruses that are members of the family Filoviridae. Both Ebola virus and Marburg virus cause 
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severe diseases in humans in the form of viral hemorrhagic fevers, which are associated with 
a high mortality rate of up to 90% (39, 40).  
There is no approved vaccine, and only a few experimental drugs have been tested in animals 
or humans with no proven efficacy for patient treatment (favipiravir) (41). As a consequence, 
filoviruses are considered biosafety level-4 pathogens. Moreover, due to the emergence of a 
new variant of Ebola virus in West Africa, there is an urgent need for efficient therapeutics. 
The only small molecule drug with potential efficacy in mice is favipiravir, with an IC50 of 67 
µM (42). Shtanko et al. have demonstrated that Retro-2 blocked infection by Ebola virus and 
Marburg virus in vitro in a dose-dependent manner with IC50 of 8.4 µM (article under 
revision). Fifty µM of Retro-2 reduced cell infection bellow 10% as compared to control. 
Retro-2 appeared to act on a late step of virus entry at the level of intracellular endocytic 
compartments. 
In summary, Retro-2 is a potential antiviral therapy that broadly inhibits viruses that use 
retrograde trafficking (adeno-associated viruses, polyomaviruses and papillomaviruses), 
although other mechanisms of viral inhibition appear to be possible as suggested for 
filoviruses.  
Poxviruses. Endosome to Golgi retrograde transport pathway proteins have been identified as 
pro-viral host factors in two independent high throughput siRNA screens of Vaccinia virus 
(VACV) (43, 44). Two recent studies investigated the role of this pathway in poxvirus 
replication in detail and showed that Retro-2 potently prevented spread of Vaccinia and 
Monkeypox viruses in cell cultures (45, 46). Most interestingly, this protective effect was not 
linked with virus entry but rather a membrane wrapping process which occurs at late stages of 
virion maturation. Two viral proteins, F13 and B5 are required for the wrapping of a small 
percentage of the single membrane intracellular mature virions into triple membrane 
intracellular enveloped virions. These are then processed further to become responsible for 
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long range spread of the virus in vivo and in vitro (47). F13 uses the endosome to trans-Golgi 
retrograde trafficking pathway to travel from early endosomes to the trans-Golgi where it co-
localizes with B5. Retro-2 treatment causes mis-localization of B5 and F13, blocks the 
wrapping process and thereby inhibits the formation of the triple-wrapped intracellular 
enveloped virions and reduces viral spread. 
6. Effects of Retro-2 on intracellular parasites 
Leishmania is a parasite responsible for leishmaniasis that affects twelve million people 
worldwide, with two million new cases each year. Although Leishmania is not considered a 
bioterrorism agent, a recent outbreak of Leishmania infantum of 446 cases in Madrid, Spain, 
between 2009 and 2012 had the characteristics of an emerging disease (7). Current treatments 
are either toxic or induce the development of drug resistant strains of the parasite and there is 
need for new anti-leishmanial drugs (48-50). Leishmania species are unicellular eukaryotes 
with well-defined nucleus and cell organelles. These parasites are internalized by 
macrophages into membrane-bound compartments called Leishmania parasitophorous 
vacuoles (LPVs) that share many characteristics with phagosomes. Previous observations 
established a role for syntaxin-5 in the development of LPVs. Since pathways involving 
syntaxin-5 had been shown to be inhibited by Retro-2 (25), Canton and Kima studied the 
effect of this compound on LPVs development (51). Retro-2 blocked LPV development 
within 2 h in cells infected with Leishmania amazonensis. In infected cells incubated for 48 h 
with Retro-2, LPV development was significantly limited and infected cells harbored four to 
five times fewer parasites than controls. In vivo experiments in mice showed that Retro-2 
limited experimental L. amazonensis infections: a 20 mg/kg intraperitoneal dose had no effect 
on the course of infection, but a 100 mg/kg dose of Retro-2 resulted in approximately a log 
less parasites compared to control (Figure 5). No toxicity was evidenced in experimental 
animals.  
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The efficacy of Retro-2 was recently demonstrated on L. donovani infantum. Retro-2 was 
active in vitro both on axenic and intramacrophage amastigotes of L. donovani infantum in a 
range from 3 to 20 µM. In addition, Retro-2 exhibited a significant reduction of parasite 
burden after a treatment at 100 mg/kg/day × 5 days on the L. donovani infantum Balb/c mouse 
model (Table 1). Therefore, this compound is able to act in vitro and in vivo on parasites 
exhibiting two different systems of housing conditions. The amastigote forms of the L. 
amazonensis complex reside in large, communal LPVs housing many parasites, whereas those 
of L. donovani infantum are located in individual LPVs. Such observations encourage to study 
the effects of Retro-2 and analogues on common pathways used by both New-World (L. 
amazonensis) and Old-World (L. donovani infantum) parasites to set up their LPVs. 
7. Effects of Retro-2 on intracellular bacteria 
Simkania negevensis is an obligate intracellular Gram-negative bacterium of the order 
Chlamydiales. Its natural host is not known and it is widespread among humans. S. negevensis 
has been associated with transmissible infections of the upper respiratory tract. Infections with 
the two closely related human pathogenic bacteria Chlamydia pneumoniae and Chlamydia 
psittaci can cause pneumonia, chronic bronchitis and chronic asthma. Chlamydia trachomatis 
is responsible for ocular and sexually transmitted infections. S. negevensis grows in host cells 
within a membrane-bound vacuole forming endoplasmic reticulum contact sites. Herweg et 
al. recently demonstrated that 75 µM of Retro-2 decreased bacterial replication both during 
primary infection down to 50% and progeny infection down to less than 40%-20% (52). Most 
interestingly, S. negevensis progeny from cells cultured in the presence of Retro-2 were 
markedly less efficient in infecting cells cultured in the absence of Retro-2. The compound 
seemed to alter the morphology of S. negevensis–containing vacuoles and replication of the 
bacteria (52). Similar results were obtained against C. trachomatis. 
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8. Optimization of Retro-2 
In order to identify more potent compounds, a structure-activity relationship (SAR) study was 
performed by Noel et al. (53). During the course of the SAR process, it appeared that the 
bioactive compound was not Retro-2 but the cyclized analog Retro-2cycl. The N-
methyldihydroquinazolinone derivatives of Retro-2 were tested in vitro for their protective 
effect against Stx2 on cellular protein synthesis. After cyclization and optimization of the 
three main moieties of Retro-2, a dihydroquinazolinone compound was identified with 
approximately 100-fold improvement of the EC50 against Stx2 cytotoxicity. Only the (S)-
enantiomer was active (Figure 6). The mode of action of this compound was similar to that of 
Retro-2, namely a selective inhibition of the retrograde transport.  
In a next step, Gupta et al. have reported the synthesis and the evaluation of a new 
enantiopure dihydroquinazolinone compound, named Retro-2.1, with improved in vitro 
protection against Stx2 (approximately 500-fold compared to Retro-2) and ricin 
(approximately 1,000-fold increased activity) (54). (S)-Retro-2.1 is currently the most potent 
molecule to counteract the cytotoxic potential of ricin and SLT with EC50 values of 23 and 
54 nM, respectively. By comparison, the (R)-enantiomer shows EC50 values of 3200 and 2400 
nM against ricin and Stx2, respectively. 
Carney et al. also described dihydroquinazolinone analogs of Retro-2cycl with improved 
potency as suppressors of human polyoma- and papillomavirus infection in vitro (37).  
Therefore, as previously demonstrated in vitro and in vivo for Retro-2, optimized derivatives 
have the potential to be developed as broad-spectrum antidotes to a wide array of pathogens, 
including toxins, viruses, intracellular bacteria and parasites that exploit retrograde trafficking 
to enter and infect the cell. 
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9. Toxins and pathogens not affected by Retro-2 
We have found bacterial toxins and viruses against which Retro-2 had no effect, neither on 
cell intoxication nor on cell infection. These include diphtheria toxin (DT), Clostridium 
botulinum neurotoxin A (BoNT/A), dengue virus serotype 4 (DENV-4), chikungunya virus 
(CHIKV) and Venezuelan equine encephalitis virus (VEEV). Table 2 indicates the maximum 
concentration at which Retro-2 was tested against each mentioned pathogen, the target cells 
and the type of assay used.  
In the case of DT and BoNT/A, the lack of action of Retro-2 is easily understood because the 
retrograde transport from the early endosomes to the trans Golgi network is not involved in 
their mechanism of action. During cell intoxication, DT is internalized into early endosomes. 
Following acidification of these compartments its catalytic domain is translocated into the 
cytosol during trafficking through the endocytic carrier vesicles of the endosome to lysosome 
degradation pathway (55). In the case of BoNT/A, the toxin is directly endocytosed in 
recycling synaptic vesicles or clathrin-coated vesicles of the nerve terminus. These vesicles 
are acidified, which triggers the translocation of the catalytic chain of the toxin into the 
cytosol where it finds its target, the SNARE protein SNAP-25 (56).  
In the case of the viruses, the absence of effect of Retro-2 on cell infection suggests that 
enveloped, positive-sense, single-stranded RNA viruses such as DENV-4, CHIKV and VEEV 
do not involve the endosome to Golgi retrograde transport machinery for entry or other steps 
of their cycle. It has been suggested that DENV-4 enters the cytoplasm after trafficking along 
the Rab5-positive early endosomes through the Rab7-positive late endosomes to the 
lysosomes or further compartments (57, 58). The alphaviruses such as CHIKV and VEEV are 
believed to enter the cell via receptor-mediated endocytosis followed by membrane fusion in 
the acidified endosomes (59, 60); however, more recent studies suggest an alternate mode of 
entry directly at the plasma membrane (61). 
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10. Conclusions 
Medical countermeasures against biothreat agents require therapeutics that are safe and have a 
large spectrum of activity without inducing possible mechanisms of resistance in case of 
living pathogens. Retro-2 and its derivatives meet these requirements. Indeed, the use of HTS 
coupled to cell-based assays allowed selecting bioactive compounds that did not affect cell 
viability (25, 32, 51). In vivo, Retro-2 and its derivative have been demonstrated to be safe, 
even at high doses (25, 32, 51). Moreover, Retro-2 is an inhibitor of retrograde transport and 
it affects syntaxin-5-dependent pathogens. As a consequence, it has a broad-spectrum activity 
that has been demonstrated both in vitro and in vivo in mice against ricin, SLT-producing 
O104:H4 E. coli and Leishmania and in vitro against AAV, polyoma-, papilloma-, Ebola, 
Marburg and poxviruses and Chlamydiales. An effect is anticipated against other toxins or 
pathogens that use retrograde trafficking. Since Retro-2 targets cell components of the host 
and not directly the pathogen, no selection of resistant pathogens is expected (4). These lead 
compounds need now to be developed as drugs for human use. This implies solving 
drugability issues (solubility, pharmacology, efficacy post disease onset) in order to obtain a 
true drug candidate. 
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Table 1. Comparison of the effects of Retro-2 and the anti-leishmanial reference molecule 
Miltefosine on the growth of L. donovani infantum in vitro on RAW macrophages and in vivo 
in Balb/c mice. 
 
Compound In vitro In vivo 
 Intra-macrophage 
amastigotes 
Treatment regimen : 
mg/kg/day × 5 days by 
i.p. route 
Reduction of parasite 
burden in the liver (%) 
 
Retro-2 20.25 ± 5.91 100 77* 
Miltefosine 0.92 ± 0.07 10 82* 
In vitro  activity: IC50 is the drug concentration inhibiting the intramacrophage parasite 
growth by 50% after a 72 h incubation time. Molecules were solubilized in pure DMSO at 30 
mM and diluted in culture medium. In vivo activity: the experiment was performed on female 
Balb/c mice 18-20 g according to the protocol described in (62). Retro-2 was solubilized in 
pure DMSO at 30 mM and diluted in saline The non-parametric Mann-Whitney U-test was 
performed to compare liver parasitic load; p value <0.05 was considered as significant versus 
untreated control mice. *p<0.01. 
 
 
 
Table 2. Toxins and viruses against which no protective activity was found for Retro-2. Cell 
types, maximum concentrations of Retro-2 and assay type are given. Retro-2 was added at 
least 1 h before and maintained during intoxication/infection. 
 
Toxins Cell line Retro-2 maximum 
concentration 
tested 
Assay type 
DT HeLa cells 30 µM Protein synthesis 
BoNT/A 
Newborn rat 
cerebellum neuron 
primary culture 
20 µM 
0.5 nM BoNT/A, 
SNAP25 cleavage 
monitoring by 
Western blot 
    
Viruses    
DENV-4 HEK293 
500 µM 
(no toxicity) 
Viral cytopathic 
effect 
CHIKV HEK293 
500 µM 
(no toxicity) 
Viral cytopathic 
effect 
VEEV VeroE6 100 µM 
Viral cytopathic 
effect 
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Figure 1. High-throughput cell-based assays. These phenotypic assays measure the effects of 
small-molecule compounds on cellular cytotoxicity induced by ricin or other toxins (23). 
Chemical compounds from stock plates (1) are added to microplates seeded with cells (2); 
toxin is then added. After incubation, different methods (3) are used to assess the effects of 
each compound on toxicity induced by ricin or other toxins: a) the CellTiter-Gloluminescent 
cell-viability assay quantifies ATP that assessed metabolically active cells. b) In luciferase 
reporter-gene assays, the enzyme activity is a measure of ongoing protein biosynthesis. c) In 
the third method, the inhibitory effect of ricin on protein biosynthesis in intact cells is 
measured through the incorporation of radioactive amino acids into neosynthesized 
polypeptides. 
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Figure 2. Cellular target of Retro-2. Toxins such as ricin and SLTs penetrate cells through the 
retrograde transport route from the plasma membrane to the endoplasmic reticulum, via 
endosomes and the Golgi apparatus (27). Retro-2 blocks toxin transport between early 
endosomes and the Golgi apparatus (25).  
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Figure 3. Protection of ricin challenge by Retro-2 (25).  
Mice were treated with the indicated doses of Retro-2 and then exposed to ricin via the nasal 
route. In each experiment, treated mice received a single intra-peritoneal dose of Retro-2 
(solubilized in pure DMSO at 30 mM and diluted in saline) 1 h prior to toxin exposure (2 
µg/kg by nasal instillation); control animals received vehicle prior to ricin administration. The 
survival curves for treated animals were statistically different from control animals (log rank 
test; p < 0.0001 for 2 mg/kg of Retro-2, p = 0.031 for 20 mg/kg; p = 0.0007 for 200 mg/kg). 
The data are reproduced from (25). 
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Figure 4. Mice protected from E. coli O104:H4 infection with Retro-2 (32).  
BALB/c mice received the O104:H4 strain by oral gavage. Intraperitoneal administration of 
mitomycin C (MMC) induced toxin release at 18, 21, and 24 h after infection. Mice received 
intraperitoneal administration of Retro-2 (100 mg/kg) at 16 and 26 h after infection. Retro-2 
was solubilized in pure DMSO and diluted in saline at 10% DMSO final concentration. Body 
weight loss (A), clinical scores (B), and survival rates (C) were monitored for 10 days after 
infection. N=20 for uninfected controls, n=40 for O104:H4-infected mice treated or not 
treated with Retro-2. * P<0.05; ** P <0.01; ***, P < 0.001. The data are reproduced from 
(32). 
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Figure 5. Retro-2 can control the course of an experimental infection with L. amazonensis 
(51). 
BALB/c mice were infected in their hind feet with 2 × 106 stationary stage cultured 
L. amazonensis promastigotes. Mice received an intra-peritoneal administration of 20 or 
100 mg/kg Retro-2, 24 h after infection. A group of mice was administered the 100 mg/kg 
dose 3 weeks after the infection was initiated. The parasite titer per foot was determined after 
9 weeks of infection. The data are reproduced from (51). 
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Figure 6. Left, structure determination of the (S)-Retro-2.1 enantiomer by X-ray 
crystallography, the only enantiomer bioactive against toxins in the nanomolar range (54). 
Right, highlight of the preferential substitutions that increase Retro-2 activity. 
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Highlights 
 
 
The molecule Retro-2 identified by HTS protects cells from ricin and Shiga toxins 
 
Retro-2 acts by blocking toxin trafficking from early endosomes to the Golgi 
 
Acting on a cellular target, Retro-2 protects cells from many intracellular pathogens 
 
Retro-2 protected mice from ricin, Shiga toxin-producing E. coli and Leishmania 
 
The optimized analogue Retro-2.1 is 1000 fold more active than Retro-2 against ricin 
